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Abstract:  We  have  shown  that  the  binding  free  energy  calculation  from  molecular 
dynamics  can be adapted successfully to  cysteine proteinases,  such as arginine-specific 
gingipain (HRgpA) from Porphyromonas gingivalis. The binding free energy obtained is in 
good agreement with the available experimental data for eight benzamidine derivatives 
including  urea and ether linker. The calculations  showed that the electrostatic energies 
between HRgpA and inhibitors were important in determining the relative affinities of the 
inhibitors to the HRgpA, with an average binding free energy of about −5 kcal/mol. The 
average structures of the eight complexes suggest that benzamidine inhibitors interact with 
Asp387,  His435,  and  Cys468  by  hydrogen  bonding  and  with  Trp508  by  hydrophilic 
interactions that are essential for the activities of benzamidine inhibitors. It can therefore be 
expected that the method provides a reliable tool for the investigation of new  HRgpA 
inhibitors. This finding could significantly benefit the future design of HRgpA inhibitors. 
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1. Introduction 
The periodontal ligament derived from connective tissue is continuously turned over in a tightly 
controlled  cycle,  which  is  consistently  challenged  by  invasion  of  pathogenic  bacteria,  such  as 
Porphyromonas  gingivalis.  They  can  accumulate  on  the gum  surface and induce an inflammatory 
OPEN ACCESS Int. J. Mol. Sci. 2010, 11                       
 
 
3253 
response from the host tissue. This immune response, which serves to destroy any foreign bodies, may 
upset homeostasis within the periodontium and lead to gingivitis [1–6]. 
Gingipains  are  one  of  the  virulence  factors  that  cause  the  development  of  periodontitis  and 
encourage the excretion of trypsin-like cysteine proteinases from the well established oral pathogen 
Porphyromonas gingivalis, a gram negative anaerobic rod, and a major causative bacterium of adult 
periodontitis. There are three major gingipains: Gingipain K (Kgp), which cleaves exclusively on the 
C-terminal side of lysine residues, and two gingipain R types (HRgpA and RgpB), which are specific 
for  Arg-Xaa  peptide  bonds.  HRgpA  and  Kgp  have  catalytic  and  adhesion/hemagglutinin  domains 
connected  by  non-colvalent  complexes,  but  RgpB  has  only  a  catalytic  domain  with  a  primary  
structure [7–13]. 
The design of irreversible inhibitors for HRgpA generally involves a peptide chain with a so-called 
warhead replacing the scissile peptide bond. The optimal peptide sequence for the inhibitor is derived 
from the best peptide substrate sequence, which can be determined through HRgpA subsite mapping 
using a peptide library. The length of the peptide portion also plays an important role in specificity. It 
is,  therefore,  possible  to  design  inhibitors  specific  for  HRgpA. The inhibitor can  then be used to 
investigate the physiological significance of the HRgpA. The warhead contains a reactive functionality 
that is attacked by the HRgpA’s catalytic nucleophile. Thus far, several warheads for HRgpA have 
been developed. Once a peptide sequence and warhead are determined, a strategic structural analysis 
relationship (SAR) study is performed to optimize the parent compound and its inhibitory potency. 
Since  the  gingipains  play  a  central  role  in  the  pathogenesis  of  gingivitis  and  periodontal  disease, 
justification exists for developing potent inhibitors as potential therapeutics. 
In the present study, the Poisson Boltzmann Solvent Accessible Surface Area (PB-SASA) method 
was used as a predictive tool to study HRgpA:inhibitor modes of interaction. Eight compounds with 
potent anti-periodontopathogenic activities [14] were selected for the current project. The experimental 
molecular structure of complexes formed between these inhibitors and HRgpA has not previously been 
reported.  To  determine  the  most  likely  model  of  interaction  between  the  studied  benzamidine 
derivatives (used as inhibitors) and HRgpA, the binding free energy was measured experimentally for 
each molecule interacting with HRgpA; in parallel, binding free energies were calculated using the PB-
SASA method for different topological models of HRgpA:inhibitor complexes. A comparison of the 
experimental free energy data with calculated values for the different binding models enabled us to 
propose the most likely mode of interaction of each studied inhibitor with HRgpA. 
2. Results and Discussion 
The binding of eight benzamidine analog inhibitors (Table 1) to the Porphyromonas gingivalis 
gingipain  R  (HRgpA),  which  is  the  non-covalent  complex  of  the  catalytic  domain  with 
hemagglutinin/adhesion domains derived from the C-terminal extension, was investigated using 
automated docking and binding free energy calculations from molecular dynamics simulations. This 
enables a detailed structural analysis of binding modes and the identification of the key inhibitor-HRgpA 
interactions that contribute to the free energy of binding. The simulated compounds are a subset of the 
inhibitors for which experimental binding affinities have been published by Krauser et al. [14], and 
they were chosen as they include both the least and most potent inhibitors from that series, and they Int. J. Mol. Sci. 2010, 11                       
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display a fairly wide variety of structural features. All inhibitors share a common benzamidine moiety, 
with substituents consisting of aromatic ring derivatives by urea and ether linkers. 
Table 1. Observed binding free energies for benzamidine derivatives. The experimental 
values of HRgpA:inhibitors binding free energy. Ki is the apparent inhibitory constant [14]. 
ΔGexp  is  the  calculated  value  of  binding  free  energy  according  to  the  equation  
ΔGexp = RT ln(Ki) for T = 298 K. All energy values are reported in kcal/mol. 
Name  Compounds  Ki (μM)  ΔGexp 
Bz1 
 
68.3  −5.676 
Bz2 
 
98.1  −5.461 
Bz3 
 
64.7  −5.708 
Bz4 
 
29.0  −6.183 
Bz5 
 
141.0  −5.247 
Bz6 
 
165.0  −5.154 
Bz7 
 
190.0  −5.070 
Bz8 
 
199.0  −5.043 
2.1. Homology Modeling 
The homology model of HRgpA is more or less structurally identical to the active sites region of the 
crystal structure of gingipain R (RgpB) with a single chain catalytic domain (PDB accession code 
1CVR [15]) with high sequence identity. For the residues that form the inhibitor binding cavity, and 
thus can be expected to be important for correct docking and molecular mechanics interactions, the 
root mean-square deviation (RMSD) of the HRgpA model compared to the RgpB crystal structure is 
0.18 Å when a theoretical model was superimposed on the crystal structure (Figure 1). It also should be 
emphasized here that HRgpA and the template RgpB have identical sequences in the cavity region, 
such that the problem of arbitrarily modeling initial (before molecular dynamics) sidechain rotamers is 
not an issue in this case. Int. J. Mol. Sci. 2010, 11                       
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2.2. Automated Docking 
Each  docking  simulation  generated  100  docked  conformations  of  each  inhibitor.  The  docking 
procedure generally generated slightly more diverse docking poses for the inhibitors containing urea or 
ether  linkers.  Encouragingly,  out  of  these  800  poses  generated,  only  a  handful  fall  outside  of  a 
consensus orientation in which the benzamidine part of the inhibitor is positioned in the binding cavity 
of the HRgpA, which is in close proximity to Asp387, His435, Cys468, and Trp508 (Figure 2). In these 
poses, one of the substituents (generally the largest one) points towards the outside of its cavity. 
Figure  1.  Panel  A  shows  the  sequence  alignment  of  the  amino  acid  sequences  of  the 
selected  region  of  HRgpA  and  the  secondary  structure  alignment.  Panel  B  shows  the 
three-dimensional homology model of HRgpA (yellow color) superimposed on the RgpB 
(green color) crystal structure [15] that was used as a template. The color coding follows 
that of the gene name in Panel A. The side chains of the residues proposed to be involved 
in inhibitor binding are shown as sticks in Panel C. 
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Figure 2. Representative binding poses of eight benzamidine analogs in core binding sites 
given by the docking calculation. 
 
Of the top 10 ranking solutions for any given inhibitor, taking only heavy atoms into account, the 
average RMSD compared to that of the top-ranked solution was approximately 2.0 Å, with few poses 
deviating >3.0 Å from the top-ranked pose. Typical results are shown for inhibitor Bz7 in Figure 3. 
Conformations that deviated more did so because the orientation of the substituents was flipped with 
respect to the other poses; however, the benzamidine part remained in the same position. Even for 
inhibitor Bz6, which showed a relatively large diversity in the suggested binding poses, the positioning 
of the benzamidine part of the inhibitor is very well determined; the positions of the benzamidine 
nitrogens–for all but five poses (all of which are among the 10 lowest ranked)–are all situated within 
the van der Waals surface of the top-ranked pose. The smallest compounds, Bz1 and Bz4, showed the 
least deviation between docking poses. In this case, the heavy atoms of the top 20 docking poses were 
all within 1.8 Å RMSD of the highest-ranked pose, with a corresponding average RMSD of 1.5 Å. 
Figure 3. Top 10 docking solutions for inhibitors: (A) Bz1; (B) Bz4; (C) Bz6 and (D) Bz7. 
The average heavy atom RMSD relative to the top-ranked pose is less than 3.0 Å. 
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2.3. Molecular Dynamics 
For each inhibitor, the top five binding poses from the automated docking experiments were chosen 
for  further  investigation  using  molecular  dynamics.  Out  of  these  40  poses,  all  but  one  had  the 
benzamidine part of the inhibitor positioned in the pivot region of the cavity. Generally, the inhibitor 
positions are stable during MD simulation, and the average structures from the production phase MD 
deviates relatively little from the docked positions. The heavy atom RMSD of the poses shown during 
MD simulation in Figure 4 are an average of approximately 2.5 Å more than their corresponding 
docked poses. The ether linkers have few or no specific interactions with the protein, and thus are fairly 
flexible during the MD simulations; whereas, the urea portions of the inhibitor are typically more 
stable in their positions, sometimes alternating between equivalent sites on the core cavity. 
2.4. Binding Free Energy 
The calculated values of HRgpA:inhibitors binding free energy for eight benzamidine derivatives 
are presented in Table 2. The binding free energy is dissected according to the approach outlined in the 
Methods section for electrostatic (ΔGelec) and non-electrostatic (ΔGvdW) contributions. The first one 
was calculated by solving the PB equations, the second by using the SASA method. The last column in 
Table 2 reports the total HRgpA:inhibitors binding free energy, which can be compared directly with 
the experimental values of binding free energy presented in Table 1. The contribution of the entropy 
term in our free energy calculations accounts for the reduction of translational and rotational freedom 
of an inhibitor and HRgpA upon binding. The correlation between the lowest calculated free energy of 
binding (obtained from PB-SASA and MD) for each inhibitor and the relative free energy differences 
derived  from  the  experimentally  determined  kinetic  constant  values  is  very  good  (Figure  5).  The 
ranking of the inhibitors also is in very good agreement with experiments. 
Comparing different contributions to the binding free energy in Table 2, one can say that the driving 
forces for inhibitor binding and eventual binding onto HBgpA are electrostatic interactions resulting 
from the burial of interfacial surface area of both HBgpA and the inhibitor. The inhibitors, especially 
Bz06 and Bz07 with relatively long side chains, may be regarded as more flexible than other inhibitors. 
Therefore, one may assume somewhat higher values than were calculated for others. This entropy cost 
is  due  to  the  advantage  of  conformational  chain  freedom  and  is  calculated  to  be  in  the  order  of 
approximately 1.3–2.2 kcal/mol for less flexible and short chains. Taking into account the entropy 
correction, we find that our calculated values of HRgpA:inhibitor binding free energy are very close to 
the experimental data. 
Although the van der Waals interactions between the HRgpA residues of the core cavity and the 
inhibitors are relatively weak compared to electrostatic forces, they play a key role in determining the 
binding affinities of the inhibitors. In fact, ranking according to ΔGvdW is identical to the ranking 
according to ΔGbind, with the exception of compound Bz7. This inhibitor also has a significantly less 
hydrophilic  substituent  than  the  other  compounds,  and  the  electrostatic  interactions  may  thus  be 
expected to contribute more to binding. Such that, although the electrostatic or polar interactions give a 
larger  overall  contribution  to  the  calculated  binding  free  energies,  that  contribution  is  relatively 
uniform for the different inhibitors as compared to non-polar interactions. In contrast, the relatively Int. J. Mol. Sci. 2010, 11                       
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large differences in the non-polar contributions are more important in determining the relative potency 
of the inhibitors. 
Figure  4.  Comparison  between  the  average  structures  from  the  production  phase  MD 
simulations in the bound state (yellow) and the corresponding docking poses (brown) used 
as starting conformations for the MD simulations. The average structures shown are from 
the simulations that yielded the lowest estimated free energy of binding. 
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Figure 5. The correlation between the free energies of binding of inhibitors (Bz1–Bz8) as 
calculated by molecular dynamics in combination with the PB-SASA method (ΔGcal from 
calculation) versus those derived from the experimental data of Krauser et al. (ΔGexp from 
experiment) [14]. The lowest binding free energy estimate from the five different poses 
simulated  for  each  inhibitor  is  plotted  against  the corresponding value calculated from 
experimentally determined Ki-values. 
 
Table  2.  The  calculated  values  for  binding  free  energies  of  HRgpA  complexed  with 
benzamidine analogs. The electrostatic portion was calculated within the PB approach; the 
nonelectrostatic contribution was calculated using SASA methods. The binding portion is 
the sum of electrostatic and non-electrostatic contributions. All energy values are presented 
in  kcal/mol.  The  uncertainties  are  the  standard  error  of  the  mean  calculated  with  200 
snapshots (50 snapshots for entropic calculations). 
Name  ΔGelec  ΔGvdW  ΔGnonp/sol  ΔGelec/sol  −TΔS  ΔGbind 
Bz1  −25.89 ±  0.09  −13.88 ±  0.12  −3.42 ±  0.01  24.14 ±  0.01  12.36 ±  0.28  −6.69 ±  0.10 
Bz2  −25.11 ±  0.01  −13.81 ±  0.12  −3.45 ±  0.01  24.24 ±  0.03  12.61 ±  0.54  −5.52 ±  0.14 
Bz3  −25.21 ±  0.11  −14.33 ±  0.12  −3.31 ±  0.01  23.23 ±  0.01  12.79 ±  0.31  −6.83 ±  0.11 
Bz4  −26.21 ±  0.10  −15.02 ±  0.13  −3.28 ±  0.01  23.05 ±  0.04  12.38 ±  0.63  −9.08 ±  0.18 
Bz5  −24.26 ±  0.11  −13.52 ±  0.07  −3.34 ±  0.01  23.51 ±  0.02  13.63 ±  0.55  −4.68 ±  0.15 
Bz6  −26.03 ±  0.10  −13.37 ±  0.16  −3.18 ±  0.01  24.31 ±  0.02  14.25 ±  0.39  −4.02 ±  0.14 
Bz7  −25.55 ±  0.08  −13.78 ±  0.11  −3.45 ±  0.01  24.61 ±  0.05  14.57 ±  0.71  −3.60 ±  0.12 
Bz8  −25.16 ±  0.09  −13.03 ±  0.13  −3.04 ±  0.01  24.15 ±  0.03  13.69 ±  0.59  −3.39 ±  0.17 
The  compound  with  the  highest  calculated  binding  affinit y  (Bz4)  has  a  strong  electrostatic 
interaction with the active sites of HBgpA and water in the bound state. The electrostatic contribution 
for the predicted model of binding Bz4 is more negative than others. This means that protonated chains 
of Bz4 prefer to stay in the HBgpA subsite and in bulk solvent equally. From this point of view, the 
relatively  high  calculated  binding  affinity  for  compound  Bz4  is  surprising,  given  its  structural 
similarity to Bz1 and Bz5 and the similar binding poses suggested by the docking procedure. Indeed, 
based solely on the differences in structure between Bz1, Bz4, and Bz5, one might even suggest that 
given the nature of the binding site, Bz4 would be expected to be the best inhibitor of the three. Since Int. J. Mol. Sci. 2010, 11                       
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Bz1 and Bz5 are identical, except for the urea linker in Bz1 and the ester linker in Bz5, and since the 
binding site is a highly hydrophilic cavity, the less polarized ester linker would be less sensitive to 
solvation and the binding site than the urea linker. 
If only inhibitor-water interactions are taken into account, a clear picture emerges in which the five 
benzyl-containing compounds (Bz1, Bz2, Bz5, Bz6, and Bz7) lose energy in electrostatic interactions 
with water when transitioning from the free state to the bound state; whereas, the rest of the inhibitors 
have roughly as strong polar interactions with water in both the free and the bound states. 
3. Computational Methods 
3.1. Homology Modeling and Docking 
The  generation  of  a  three-dimension  homology  model  of  gingipain  R  type  A  (HRgpA)  from 
porphyromonas gingivalis using MODELLER (www.salilab.org) was based on the complex crystal 
structure of gingipain R type B (RgpB), using its peptidyl inhibitor (PDB accession code 1CVR [15]) 
as a template. Only the catalytic domain (residues 225–652, HRgpA numbering, which is the catalytic 
domain) of HRgpA was included in the model. In this region, the sequence similarity between RgpB 
and HRgpA is approximately 90%, and the sequences align without any gaps at all, which allows the 
construction  of  a  very  reliable  homology  model.  Next,  the  system  was  prepared  for  docking  and 
molecular dynamics (MD) simulations. 
All  the  benzamidine  derivatives  that  were  used  as  inhibitors  were  energy-minimized  with  the 
MMFF force field [16] before docking. Automated docking of the inhibitors was performed using the 
flexible  docking  (FD)  module  [17]  in  Discovery  Studio  2.0  (Accelrys  Inc.). To predict optimized 
binding poses for flexible inhibitors in a flexible binding site of HRgpA, the FD module was used in 
combination with ChiFlex to generate side chain conformations of HRgpA; CatConf/CAESAR was 
used for building diverse low energy conformations of inhibitors; LibDock was used for computing 
hotspot  locations;  ChiRotor  was  used  for  modifying  side  chain  conformations  of  HRgpA;  and 
CDOCKER was used to determine annealing and minimizing inhibitor poses. The active site radius 
was set to 7.0 Å, centered near a point on the symmetry axis of the center of mass (CM) of the binding 
cavity.  This  positioning  of  the  docking  sphere  enables  the  inhibitors  to  explore  different  docking 
conformations within the entire cavity. LigandFit [18] was then set to terminate the docking if the top 
three poses for an inhibitor were within 1.5 Å RMSD. The docking procedure was performed, and the 
complexes were again solvated for molecular dynamics and free energy calculations. 
3.2. Molecular Dynamics Simulation 
All MD calculations were conducted using the program AMBER with the modified all-hydrogen 
AMBER parameter set [19–22]. Partial atomic charges were assigned to the inhibitors, analogous with 
the charges specified in the fragment library. A 30 Å simulation sphere was used for both simulations 
in the bound and unbound states with inhibitors. The same sphere center was used as was described for 
the docking procedure, and it was again solvated with TIP3 water [23]. All atoms outside the 30 Å 
sphere were tightly restrained throughout the simulations. Water molecules at the surface of the sphere 
were subjected to radial and polarization constraints to mimic the properties of bulk water [24]. Before Int. J. Mol. Sci. 2010, 11                       
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data collection, each simulation system was heated in a stepwise manner from 10 to 300 K with all 
solute heavy atoms subject to strong (10–25 kcal/mol Å
2), harmonic positional restraints. Next, all 
simulations  of  the  inhibitors  in  the  bound  state  were  equilibrated  without  restraints  for  500  ps, 
followed by 250 ps of production phase MD. The final structure of the HRgpA:inhibitor complex was 
obtained  after  the  equilibration  step  was  used  as  a  starting  structure  for  the  binding  free  energy 
calculation. To assess the problem of conformational sampling when simulating the inhibitors in the 
unbound state in water, 10 replicate water simulations of 5 ns each were performed for each inhibitor, 
with starting conformations generated by high temperature MD. For all production phase MD, a 1-fs 
time  step  was  used  along  with  the  SHAKE  procedure  for  all  solvent  bonds  [25].  Non-bonded 
interactions across the simulation sphere boundary were excluded. A non-bonded cutoff of 10 Å was 
used, with electrostatic interactions outside the cutoff treated with the local reaction field multipole 
expansion [26], except for the inhibitor, which had no cutoff applied to any of its interactions. 
3.3. Free Energy Calculation 
Binding affinities were calculated using MD in combination with the Poisson Boltzmann Solvent 
Accessible Surface Area (PB-SASA) method [27–35], which uses simulations of the HRgpA:inhibitor 
complex to calculate the change in free energy associated with binding to the protein, according to the 
following equation: ΔGbind = ΔGMM + ΔGsolv − TΔS, where ΔGbind is the binding free energy, ΔGMM is 
the molecular mechanical energy, ΔGsolv is the solvation energy, and TΔS is the entropy contribution. 
The molecular mechanical energy is calculated by the following equation: ΔGMM = ΔGelec + ΔGvdW, 
where  ΔGelec  and  ΔGvdW  represent  electrostatic  and  van  der  Waals  energies,  respectively.  In  the  
PB-SASA method, the difference in interaction energies between the inhibitors and their surrounding 
residues are used to calculate the free energy of binding through the equation. MD simulations of the 
interacting molecules were conducted in water at T = 298 K and P = 1 atm using TIP3 water. The free 
energy  of  HRgpA:inhibitors  association  in  aqueous  solution  (ΔGsolv)  can  be  divided  into  polar 
(electrostatic)  (ΔGelec_solv)  and  non-polar  (non-electrostatic)  (ΔGnpol_solv)  terms  [36].  The  
Poisson-Boltzmann equations have been shown to provide an accurate description of the electrostatic 
interactions between receptor and ligands. This approach was used in the present study to calculate 
electrostatic contributions to the binding free energy, while non-polar contributions were calculated 
using the SASA method [37–39]. Additionally, the transfer of a molecule from a phase of ε = 4 to a 
phase of ε = 78 justifies the application of the microscopic surface tension coefficient used in the 
SASA methods. 
4. Conclusions 
We have reported homology modeling, automated docking of benzamidine derivatives as inhibitors, 
and  binding  free  energy  calculations  from  molecular  dynamics  simulations  of  the  gingipain  R 
(HRgpA). The 2.0 Å crystal structure of the very closely related gingipain R (RgpB) [14] was used as a 
template for the homology modeling. Automated docking of eight benzamidine derivatives with known 
binding affinities was performed using the resulting three-dimensional model. For the top five docking 
solutions for each inhibitor, the structural and thermodynamic stabilities of the docked complexes were 
investigated further using the PB-SASA method in combination with MD simulations. The results Int. J. Mol. Sci. 2010, 11                       
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from these simulations strongly suggest that all of the inhibitors bind to the RgpB in a manner similar 
to that of the benzamidine moiety of the inhibitors binding into HRgpA. Of the 800 suggested docking 
poses  generated  by  automated  docking,  only  a  handful  are  positioned  in  a  manner  significantly 
different from the top-ranked poses, and the deviating poses are typically among the lowest ranked for 
that inhibitor. Furthermore, the inhibitors are found to be structurally stable in their docked positions 
during unrestrained MD simulations. 
The bisbenzamidine inhibitors contain two aromatic rings linked by spacers with differing lengths 
and chemical characteristics. The bisbenzamidine inhibitors containing a urea moiety linking the two 
aromatic rings, such as compounds Bz1–4, were better inhibitors for both HRgpA and RgpB. Those 
bisbenzamidines which contain the less polar ether linker, such as Bz5–8, were less efficient inhibitors. 
Both isoforms of gingipain R showed a strong preference for the amidino group in the 4 position of the 
aromatic ring rather than at the 3 position [14]. Bisbenzamidine Inhibitors, which had a urea linker and 
the amidine substituent at the 3 position, were poorer inhibitors. 
The  accurate  characterization  of  solvation  effects  is  critical  in  the  thermodynamic  process  of 
protein-ligand binding. The calculation of solvation free energies is a more tractable problem than 
predicting binding free energies, since the solvent molecules equilibrates more quickly around a ligand 
than around the binding site of the protein. The prediction of solvation free energies also provides a 
surrogate for the biologically relevant process of transferring a ligand from solution (high-dielectric 
environment) to the binding site of a protein (low-dielectric region) and, therefore, is an important step 
toward predicting accurate binding free energies. In the present study, the values of the free energy for 
HRgpA:bisbenzamidine complexes in TIP3 model are found to be in reasonably good agreement with 
the experimental values. From the present investigation, we conclude that the complexes in the TIP3 
model are able to accurately describe the interaction between HRgpA and bisbenzamidine derivatives. 
But, further work on conducting the simulation in other water models such as TIP4P, SPC, and SPC/E 
models, could help to bring the accuracy level of binding free energy predictions to the point where 
they can provide substantial value. 
In  this  work,  the  predicted  binding  modes  of  benzamidine  derivatives  to  HRgpA  are  strongly 
supported by the following facts: The high sequence identity between RgpB and HRgpA in the binding 
region;  a  consensus  docking  pose  for  all  inhibitors,  which  is  also  found  to  be  stable  during  MD 
simulations; and an excellent correlation between observed and calculated binding affinities, where the 
latter were obtained from detailed all-atom energetic calculations.  
Therefore, this model for benzamidine analog inhibitor binding to HRgpA, based on the RgpB 
template, is one of the few currently available examples of detailed three-dimensional models for how 
drug-like compounds interact with Arg-gingipain with the hemaglutaminine domain. 
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